Cal. Health and Safety Code § 150401
Cal. Health and Safety Code § 150401
California · California Health and Safety Code · Status: effective · Effective 2022-01-01
Cite this
- Citation
- Cal. Health and Safety Code § 150401, California, version 1 as recorded 2026-07-25, yourstate.us, https://yourstate.us/provision/876897
- Permanent ID
ys:prov:876897@1- SHA-256
70145ea843e235edb1f2addd2c8767594b3703f58430c3949e0c15d061b78cb5
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
For purposes of this division, the following definitions apply:
(a) “Donor” means an individual who donates unused prescription drugs to a participating practitioner for the purpose of redistribution to established patients of that practitioner.
(b) “Ineligible drugs” means drugs that are not able to be accepted for redistribution as part of the program established pursuant to this division. “Ineligible drugs” include all controlled substances, including all opioids, all compounded medications, injectable medications, drugs that have an approved United States Food and Drug Administration Risk Evaluation and Mitigation Strategy (REMS) requirement, and all growth factor medications.
(c) “Participating practitioner” means a person who is licensed to practice medicine by the Medical Board of California and is board certified in medical oncology or hematology and is registered with a surplus medication collection and distribution intermediary.
(d) “Recipient” means an individual who voluntarily receives donated prescription medications.
(e) “Surplus medication collection and distribution intermediary” means an entity licensed pursuant to Section 4169.5 of the Business and Professions Code as a surplus medication collection and distribution intermediary, as described in Section 150208.
(f) “Unused cancer medication” or “medication” means a medication or drug, including a “dangerous drug” as defined in Section 4022 of the Business and Professions Code or a “drug” as defined in Section 4025 of the Business and Professions Code, that is prescribed as part of a cancer treatment plan and is in its original container or packaging.